Daniel Simon, MD
- Division Chief, Cardiovascular Medicine
- Chief Academic Officer
Dr. Simon is the President, Medical Centers, University Hospitals Health System; and Professor of Medicine, Case Western Reserve University School of Medicine. He graduated summa cum laude from Harvard College. After earning his medical degree from Harvard Medical School, he completed his internal medicine residency and cardiovascular medicine fellowship at Brigham and Women’s Hospital and interventional cardiology training at Beth Israel Hospital, Harvard Medical School. He joined the faculty of Brigham and Women’s Hospital where he rose through the ranks to Associate Professor of Medicine, Harvard Medical School.
A recipient of numerous research awards, Dr. Simon was elected into the American Society for Clinical Investigation, Association of University Cardiologists, and the Association of American Physicians. He is a recipient of the prestigious MERIT Award from the National Heart, Lung, and Blood Institute and the 2016 Distinguished Scientist Award from the American College of Cardiology. He is a Fellow of the American College of Cardiology, the American Heart Association, and the Society of Cardiac Angiography and Interventions. Dr. Simon’s main area of research interest is the role of inflammation in vascular injury and repair. His research is supported by grants from the National Institutes of Health, the Prentiss Foundation, the Medtronic Foundation, and the Harrington Discovery Institute. Using cutting-edge transcriptional profiling approaches, his laboratory has identified a novel biomarker called MRP-8/14 that predicts the risk of future heart attack and stroke. Dr. Simon is the Co-Founder of Sujana Biotech, a start-up biotechnology company developing novel monoclonal antibodies for a range of inflammatory and vascular disorders. The company’s lead product is in the early preclinical phase of development. He is an active interventional cardiologist and continues to play a leading role in national and international clinical trials investigating new devices, anti-thrombotic drugs, and regenerative medicine therapies. He has been recognized in Best Doctors in America and U.S. News Top Doctors. Dr. Simon is the official cardiovascular health care partner of the NFL’s Cleveland Browns. He has published extensively in peer-reviewed basic science and clinical journals. Dr. Simon has served on the Editorial Boards of Circulation and Journal American College Cardiology and was recently appointed to the Editorial Board of JAMA Cardiology. He also serves on the Board of Directors of Playhouse Square, University Circle Inc. and Cleveland Institute of Art.
- Cardiovascular Medicine
- Cell-based and Stem Cell Therapies
- Clinical Trials Research
- Coronary Artery Disease (CAD)
- Interventional Cardiology
Patient Satisfaction Reviews
5 out of 5
- Interventional Cardiology - American Board of Internal Medicine
- Cardiovascular Disease - American Board of Internal Medicine
Fellowship | Interventional Cardiology
Interventional Cardiology - Beth Israel Deaconess Medical Center (1993 - 1995)
Fellowship | Cardiovascular Disease
Cardiovascular Disease - Brigham And Women's Hospital (1989 - 1992)
Residency | Internal Medicine
Internal Medicine - Brigham And Women's Hospital (1988 - 1989)
Internship | Internal Medicine
Internal Medicine - Brigham And Women's Hospital (1987 - 1988)
Harvard Medical School (1987)
Harvard University (1983)
University Hospitals is committed to transparency in our interactions with industry partners, such as pharmaceutical, biotech, or medical device companies. At UH, we disclose practitioner and their family members’ ownership and intellectual property rights that are or in the process of being commercialized. In addition, we disclose payments to employed practitioners of $5,000 or more from companies with which the practitioners interact as part of their professional activities. These practitioner-industry relationships assist in developing new drugs, devices and therapies and in providing medical education aimed at improving quality of care and enhancing clinical outcomes. At the same time, UH understands that these relationships may create a conflict of interest. In providing this information, UH desires to assist patients in talking with their practitioners about industry relationships and how those relationships may impact their medical care.
UH practitioners seek advance approval for certain new industry relationships. In addition, practitioners report their industry relationships and activities, as well as those of their immediate family members, to the UH Office of Outside Interests annually. We review these reports and implement management plans, as appropriate, to address conflicts of interest that may arise in connection with medical research, clinical care and purchasing decisions.
View UH’s policy (PDF) on practitioner-industry relationships.
As of December 31, 2016, Daniel Simon disclosed the following Outside Relationships with Industry:
- - Abbott Laboratories - Consulting
- - Cordis Corporation - Consulting
- - Medtronic - Consulting
- - BioMotiv/Sujana Biotech - Ownership
- - Medtronic, Inc. - Honoraria